3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Glioblastoma
4
Small Cell Lung Carcinoma
2
Breast Neoplasms
2
Pancreatic Neoplasms
1
Pancreatic Cancer Metastatic
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lung Neoplasms
1
Gliosarcoma
1
Glioma
1
Chondrosarcoma
1
Cholangiocarcinoma
1
Carcinoma, Intraductal, Noninfiltrating
1
Brain Neoplasms
1
Arthritis, Rheumatoid
1
Interventions
Adalimumab
13
Methotrexate
11
Etanercept
10
Rituximab
5
Abatacept
5
tocilizumab
4
olokizumab
4
tofacitinib
3
golimumab
3
Infliximab
3
Tumor Necrosis Factor Inhibitors
2
Saline Solution
2
RC-18
2
Nivolumab
2
Leflunomide
2
Certolizumab Pegol
2
Antirheumatic Agents
2
veltuzumab
1
upadacitinib
1
secukinumab
1
sarilumab
1
mavrilimumab
1
entecavir
1
cabozantinib
1
baricitinib
1
andecaliximab
1
Vitamin D
1
Vaccines
1
TACI receptor-IgG Fc fragment fusion protein
1
Syringes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Arthritis, Rheumatoid
×
Chloroquine
×
Clear all
NCT03449758
2022-04-28
SariPRO
Sanofi
Phase 4
Completed
84 enrolled
36 charts